

Modified Bone Marrow Stromal Cells Therapy for Central Nervous System Disorders

Yu Bin Deng¹, RuiRui Yang¹, Cai Xia Xu¹ and XiuQuan Zhang^{2*}

¹Research Center of Translational Medicine, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou 510080, China

²University of Utah School of Medicine, Salt Lake City, Utah 84132, USA

*Corresponding author: Xiu Quan Zhang, University of Utah School of Medicine, Salt Lake City, Utah 84132 USA, Tel: +1-801-585-3117; Fax: +801-581-3552, E-mail: xiuquan.zhang@hsc.utah.edu

Rec date: May 10, 2014, Acc date: May 24, 2014, Pub date: May 27, 2014

Copyright: © Deng YB, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

This article concluded our serial studies on the therapeutic protective effects of modified bone marrow stromal cells on central nervous injury. Hope this will provide a preclusion of transition of central nervous disease treatment from experimental treatment to the idea of clinical application.

Keywords: Stromal cell; Ischemia; Spinal injury

Abbreviations

BMSC: Bone Marrow Stromal Cells; CNS: Central Nervous System; OEC: Olfactory Ensheathing Cell; Sal B: Salvianolic acid B; EPO: Erythropoietin; SCI: Spinal cord Ischemia; VEGF: Vascular Endothelial Growth Factor; Gd-DTPA: Gadolinium-diethylenetriaminepenta-acetic acid; SCD-1: Stromal Cell-Derived factor 1; CXCR4: Chemokine Receptor type 4

Editorial

Stem cells are a kind of cells characterized of species diversity, self-replication and renewal ability, high proliferation potential and multiple differentiation potential [1-4]. Compared with other types of stem cell transplantation, treatment using Bone Marrow Stromal Cells (BMSCs) has more advantage, which has rich resources, easy to access, multiple potential, ethical limits, subculture amplification etc. It is popular attended as appropriate seed cells [5,6]. There were increasing evidences that transplanted BMSCs significantly promote nervous functional recovery after Central Nervous System (CNS) injured in the animal models [7-9]. The BMSCs treatment for neural disease would be of great benefit, but the mechanism is still unclear [6,10,11]. Focusing on cerebral ischemia and spinal cord injury, we concluded our studies of how the modified BMSCs protect the target organs and potential strategies, which may contribute to successful clinical transplantation and outcomes improvement of central nervous system disease.

Stem cell therapies provide unique opportunities for diseases of the Central Nervous System [12-14]. By co-transplantation of BMSCs and embryo Olfactory Ensheathing Cell (OECs) *in vivo*, we confirmed that spinal nervous cells conduction performance improved and the histological analysis suggested that the BMSCs differentiating into neurons cell proportion increased significantly. In addition, axons dyeing were densely distributed in the damage area. BMSCs and OECs transplantation together to treat spinal cord injury may be a potential method to improve the treatment of SCI [15]. To explore the cellular protective mechanisms of BMSCs, we transplanted BMSCs into

ischemia rats and found that they could promote the functional recovery through secrete neurotrophic factors. BMSCs protect hypoxia-induced PC12 cells against apoptosis at least in part through the VEGF/PI3K/Akt/FoxO1 pathway [16]. Another study revealed that the protective effects of BMSCs against PC12 cell apoptosis induced by CoCl₂ might be dependent on erythropoietin (EPO) expression, at least in part, via the regulation of Bcl-2 family members and caspases [17].

Treatment of ischemic stroke with BMSCs transplantation combining with Salvianolic acid B may improve the removal of thrombus and stimulation of neogenesis [18,19]. In order to improve the survival rate of stem cells after transplantation, Salvianolic acid B (Sal B) was found effectively inhibit the release of TNF- α then protecting BMSCs from the inflammation stimulation and promoting the leg's function recovery in SCI rats [20]. Study in rat also found that Sal B could directly reduce the generation of reactive oxygen levels in the cell oxidative stress situation, inhibiting apoptosis genes before the activation of p-ERK1/2. All these findings demonstrated that Sal B could enhance BMSCs oxidative stress resistance, reducing the H₂O₂ stimulation caused by cell apoptosis [21]. In other studies, the results indicated that Curcumin could promote the spinal cord repair via inhibition of glialscar formation and inflammation [22,23]. It could block cell injury by virtue of its antioxidant properties [24]. Curcumin is a double-edgeds word for both JAK2/STAT3 and NF- γ B inhibition in injured spinal cord [23].

Combination stem cells with biomaterials is another direction in the research of the central nervous system injury [25,26]. Some research had constructed biological composite materials to control the releasing of neurotrophic factors and stem cells transplantation. It confirmed that the combined transplantation could provide functional benefits [27,28]. However, how to choose the effective way of the combination of growth factors and materials need further exploration [29].

For further facilitate the therapeutic effects using BMSCs, cell imaging plays a pivotal role in this regenerative therapy study [31]. When BMSCs were labled by Gadolinium-diethylene triamine penta-acetic acid (Gd-DTPA), the migration and proliferation of BMSCs could be traced by MRI in animal models. We confirmed that BMSCs spread through the damage areas to promote the functional recovery 14 day after transplanted *in vivo* [32]. Our previous observations indicated that systemically administered BMSCs could migrate to the ischemic lesion of brain along with the olfactory-thalamus and hippocampus-cortex route. We revealed that the interaction of locally produced SDF-1 α and CXCR4 expressed on the BMSCs surface played an important role in the migration of transplanted cells [33].

Gratifying progress has been made in the therapeutic study with BMSCs transplantation to some certain disease, but outcome of neural disease therapy remained limited improvement in clinic. This may be because of the neural disorder is more complex, involving more cell types, more complicated cerebral blood circulation and micro environment [2]. We have to face more clinical hurdles including (1) limited engraftment, survival, and proliferation; (2) immunogenicity with allogenic transplantation; (3) poor differentiation, maturation, and integration [34]. And yet, the successful experimental nervous regeneration therapy with modified BMSCs will provide a prelude of central nervous disease treatment in clinic.

References

1. Shang AJ, Hong SQ, Xu Q, Wang HY, Yang Y, et al. (2011) NT-3-secreting human umbilical cord mesenchymal stromal cell transplantation for the treatment of acute spinal cord injury in rats. *Brain Res* 1391: 102-113.
2. Artegiani B, Lange C, Calegari F (2012) Expansion of embryonic and adult neural stem cells by in utero electroporation or viral stereotaxic injection. *J Vis Exp* 68: 4093.
3. Deng YB, Ye WB, Hu ZZ, Yan Y, Wang Y, et al. (2010) Intravenously administered BMSCs reduce neuronal apoptosis and promote neuronal proliferation through the release of VEGF after stroke in rats. *Neurol Res* 32: 148-156.
4. Chen C, Cheng Y, Chen J (2011) Transfection of Noggin in bone marrow stromal cells (BMSCs) enhances BMSC-induced functional outcome after stroke in rats. *J Neurosci Res* 89: 1194-1202.
5. Lehwald N, Duhme C, Wildner M, Kuhn S, Furst G, et al. (2014) HGF and SDF-1-mediated mobilization of CD133+ BMSC for hepatic regeneration following extensive liver resection. *Liver Int* 34: 89-101.
6. Isasi R, Andrews PW, Baltz JM, Bredenoord AL, Burton P, et al. (2014) Identifiability and privacy in pluripotent stem cell research. *Cell Stem Cell* 14: 427-430.
7. Kuroda S, Houkin K (2013) Translational challenge for bone marrow stroma cell therapy after stroke. *Front Neurol Neurosci* 32: 62-68.
8. Tian Y, Deng YB, Huang YJ, Wang Y (2008) Bone marrow-derived mesenchymal stem cells decrease acute graft-versus-host disease after allogeneic hematopoietic stem cells transplantation. *Immunol Invest* 37: 29-42.
9. Wei B, Jin C, Xu Y, Du XT, Yan C, et al. (2014) Chondrogenic differentiation of marrow clots after microfracture with BMSC-derived ECM scaffold in vitro. *Tissue Eng Part A*.
10. Bragado Alonso S, Schulze-Steikow M, Calegari F (2014) Cell cycle activity of neural precursors in the diseased mammalian brain. *Front Neurosci* 8: 39.
11. Knoblich JA (2008) Mechanisms of asymmetric stem cell division 132: 583-597.
12. Nguyen PK, Riegler J, Wu JC (2014) Stem Cell Imaging From Bench to Bedside *Cell Stem Cell* 14: 431-444.
13. Oda Y, Tani K, Asari Y, Quintanilha LF, Haraguchi T, et al. (2014) Canine Bone Marrow Stromal Cells Promote Functional Recovery in Mice with Spinal Cord Injury. *J Vet Med Sci*
14. Wang L, Lin Z, Shao B, Zhuge Q, Jin K (2013) Therapeutic applications of bone marrow-derived stem cells in ischemic stroke. *Neurol Res* 35: 470-478.
15. Deng YB, Liu XG, Liu ZG, Liu XL, Liu Y, et al. (2006) Implantation of BM mesenchymal stem cells into injured spinal cord elicits de novo neurogenesis and functional recovery: evidence from a study in rhesus monkeys. *Cytotherapy* 8: 210-214.
16. Zhong Q, Zhou Y, Ye W, Cai T, Zhang X, et al. (2012) Hypoxia-inducible factor 1- α -AA-modified bone marrow stem cells protect PC12 cells from hypoxia-induced apoptosis, partially through VEGF/PI3K/Akt/FoxO1 pathway. *Stem Cells Dev* 21: 2703-2717.
17. Mo SJ, Zhong Q, Zhou YF, Deng DB, Zhang XQ (2012) Bone marrow-derived mesenchymal stem cells prevent the apoptosis of neuron-like PC12 cells via erythropoietin expression. *Neurosci Lett* 522: 92-97.
18. Zhao YH, Guan Y, Wu WK (2012) Potential advantages of a combination of Chinese Medicine and bone marrow mesenchymal stem cell transplantation for removing blood stasis and stimulating neogenesis during ischemic stroke treatment. *J Tradit Chin Med* 32: 289-292.
19. Ormond DR, Shannon C, Oppenheim J, Zeman R, Das K, et al. (2014) Stem cell therapy and curcumin synergistically enhance recovery from spinal cord injury. *Plos One* 9: e88916.
20. Lu B, Ye Z, Deng Y, Wu H, Feng J (2010) MEK/ERK pathway mediates cytoprotection of salvianolic acid B against oxidative stress-induced apoptosis in rat bone marrow stem cells. *Cell Biol Int* 34: 1063-1068.
21. Li S, Deng Y, Feng J, Ye W (2009) Oxidative preconditioning promotes bone marrow mesenchymal stem cells migration and prevents apoptosis. *Cell Biol Int* 33: 411-418.
22. Samini F, Samarghandian S, Borji A, Mohammadi G, Bakaian M (2013) Curcumin pretreatment attenuates brain lesion size and improves neurological function following traumatic brain injury in the rat. *Pharmacology, biochemistry, and behavior* 110: 238-244.
23. Wang YF, Zu JN, Li J, Chen C, Xi CY, et al. (2014) Curcumin promotes the spinal cord repair via inhibition of glial scar formation and inflammation. *Neuroscience* 260: 51-56.
24. Chan WH, Wu HJ (2006) Protective effects of curcumin on methylglyoxal-induced oxidative DNA damage and cell injury in human mononuclear cells. *Acta Pharmacol Sin* 27: 1192-1198.
25. Shang AJ, Hong SQ, Xu Q, Wang HY, Yang Y, et al. (2011) NT-3-secreting human umbilical cord mesenchymal stromal cell transplantation for the treatment of acute spinal cord injury in rats. *Brain Res* 1391: 102-113.
26. Hu MS, Maan ZN, Wu JC, Rennert RC, Hong WX, et al. (2014) Tissue Engineering and Regenerative Repair in Wound Healing. *Ann Biomed Eng*.
27. Bakhtyari M, Marzban M, Mehdizadeh M, Joghataei MT, Khoei S, et al. (2010) Comparison of transplantation of bone marrow stromal cells (BMSC) and stem cell mobilization by granulocyte colony stimulating factor after traumatic brain injury in rat. *Iranian Biomed J* 14: 142-149.
28. Wang LJ, Zhang RP, Li JD (2014) Transplantation of neurotrophin-3-expressing bone mesenchymal stem cells improves recovery in a rat model of spinal cord injury. *Acta Neurochir*.
29. Wu HF, Cen JS, Zhong Q, Chen L, Wang J, et al. (2013) The promotion of functional recovery and nerve regeneration after spinal cord injury by lentiviral vectors encoding Lingo-1 shRNA delivered by Pluronic F-127. *Biomaterials* 34: 1686-1700.
30. Troy A, Cadwallader AB, Fedorov Y, Tyner K, Tanaka KK, et al. (2012) Coordination of satellite cell activation and self-renewal by Par-complex-dependent asymmetric activation of p38 α /beta MAPK. *Cell stem cell* 11: 541-553.
31. Shen J, Cheng LN, Zhong XM, Duan XH, Guo RM, et al. (2010) Efficient in vitro labeling rabbit neural stem cell with paramagnetic Gd-DTPA and fluorescent substance. *Eur J Radiol* 75: 397-405.
32. Liu Y, He ZJ, Xu B, Wu QZ, Liu G, et al. (2011) Evaluation of cell tracking effects for transplanted mesenchymal stem cells with jetPEI/Gd-DTPA complexes in animal models of hemorrhagic spinal cord injury. *Brain Res* 1391: 24-35.
33. Wang Y, Deng Y, Zhou GQ (2008) SDF-1 α /CXCR4-mediated migration of systemically transplanted bone marrow stromal cells towards ischemic brain lesion in a rat model. *Brain Res* 1195: 104-112.
34. Sasaki JL, Matsumoto T, Imazato S (2014) Oriented bone formation using biomimetic fibrin hydrogels with three-dimensional patterned bone matrices. *J Biomed Mater Res A*.